Gemfibrozil (CI-719) has proved to be an effective agent in reducing the plasma triglyceride levels in experimental animals and in patients with endogenous hypertriglyceridaemia. We have confirmed these findings. Fig 1 shows the effects of CI-719 on plasma triglyceride concentrations in 4 patients with endogenous hypertriglyceridcmia maintained on an isocaloric diet (providing 35 calories/kg per day) for a period of six months. During therapy with 400 mg/day of CI-719, the plasma triglyceride concentration was reduced by a mean 35%, while the administration of 800 mg/day reduced the level by 49%. On withdrawal of therapy, the plasma triglyceride concentration returned to the pretreatment level.
We have also shown that the reduction in serum triglvceride concentration during the Dr A H Kissebah period of therapy was due to a decrease in the circulating level of plasma very low density lipoproteins (VLDL). Since the ultimate therapeutic objective in the therapy of hypertriglyceridoemia is to restore normal lipid homeostasis (rather than the treatment of plasma triglyceride levels), it is important to understand the mechanism of action of the drug, as well as the metabolic fate of plasma lipoproteins, in patients receiving long term therapy. This report discusses some of the results we have obtained in an attempt to clarify these points. Mechanism ofthe Hypotriglyceridemic Action ofCI-719 In 4 subjects with endogenous hypertriglyceridemia, the kinetics of plasma VLDL transport during treatment with CI-719, and while the patients were receiving no therapy, have been examined. The plasma VLDL molecule was labelled in two positions. The triglyceride moiety, which is the major lipid component of plasma VLDL, was labelled endogenously during a two hour infusion of a tracer dose of 14C-palmitate. The B-apoprotein comprising 40-64% of the total VLDL apoprotein was selectively labelled with 13'I. The patients' plasma VLDL was isolated by ultracentrifugation, iodinated with 131I and incubated with the patients' own HDL fraction to delete the label from moieties other then the B-apoprotein. Using this technique, about 90% of the total VLDL label was bound to the B-apoprotein. The labelled lipoprotein was reinjected into the patients at the end of the Similarly, the turnover rates of plasma VLDL B-apoprotein in the hypertriglyceridemic patients were higher than normal and were also decreased by the administration of CI-719. Since these patients were in a steady state during the experimental period, the increase in the absolute turnover of these moieties suggests that the increase in plasma VLDL concentration in the untreated patients was due to an enhanced production of these molecules and that the treatment with CI-719 restored the production rates to normal. Furthermore, the close correlation between the turnover rates of the triglyceride and the Bapoprotein in plasma VLDL before and after treatment (Fig 2) suggests that the drug produces proportionate effects on the transport rate of both components. This is consistent with our findings of a constant triglyceride/protein ratio in plasma VLDL in patients under treatment with CI-719 (Kissebah, Alfarsi, Adams, Seed etal. 1976 Barter & Nestel (1973) used a simultaneous infusion of 3H-palmitate and 14C-glucose to estimate the proportion of endogenous triglyceride fatty acids derived from either de novo lipogenesis or the esterification of plasma FFA. They concluded that in normal subjects, as well as hypertriglyceridwmic patients, virtually all plasma triglyceride fatty acids were derived from the hepatic esterification of plasma FFA, and that lipogenesis from glucose constitutes an unimportant contribution in subjects on a normal diet.
Our previous studies also suggest that the enhanced plasma FFA flux seen in patients with endogenous hypertriglyceridtmia correlates significantly with the increased VLDL triglycerides and apoprotein production, suggesting that the increased availability of plasma FFA constitutes a major factor in the pathogenesis of the syndrome . Indeed, agents which effectively inhibit the release of FFA to the plasma, such as nicotinic acid and clofibrate, produce a proportionate decrease in plasma VLDL triglyceride production and a fall in plasma triglyceride concentration .
We have therefore measured the turnover rate of plasma FFA in our patients in the untreated state and following therapy with CI-719, to examine the possibility that the drug might exert its action via an effect on peripheral lipolysis. As shown in Table 2 , the tunover rates and circulating mass of plasma FFA in the hypertriglyceridmmic patients were increased. During treatment with CI-719, the turnover of plasma FFA was restored to normal. Although the circulating mass of FFA was also reduced, the values remained higher than the upper limit seen in the normolipmmic subjects. These results suggest that the drug also inhibits the hepatic uptake of plasma FFA. The combination of these effects decreases the hepatic supply of fatty acids available for esterification to triglycerides, and could account for the reduction in hepatic VLDL triglyceride production seen during CI-719 therapy. The decrease in the carrier apoprotein production, on the other hand, indicates that the drug also exerts an effect on the hepatic synthesis of these molecules.
Metabolic Fate ofPlasma VLDL andLDL Apoprotein in Patients Receiving CI-719 Therapy Several recent studies have indicated that the fate of plasma VLDL apoprotein involves in part its conversion to plasma LDL, and that this conversion provides the major source of plasma LDL molecules (Sigurdsson et al. 1975; Alfarsi, .
In some species, however, this conversion accounts for only a minor fraction of plasma VLDL metabolism while the major part removed from the circulation is degraded, presumably in the liver, without conversion to LDL (Eisenberg & Rachmilewitz 1973) . Fig 3 is a schematic representation of the pathways for VLDL and LDL metabolism during the process of their removal from the plasma. The relative importance of each of these pathways could provide a reasonable explanation for the interspecies differences in plasma low density lipoprotein (LDL) levels and possibly for their susceptibility to arterial disease. Furthermore, the efficacy of any hypolipidwmic agent has to be evaluated with regard to its effects on any of these pathways.
Using 1311 VLDL selectively labelled in the B-apoprotein and 1251 LDL injected simultaneously into the patient, we were able to quantitate the conversion of plasma VLDL to LDL in man. From the urinary excretion of the isotopes we have also estimated the quantity of VLDL B-apoprotein subjected to degradation (for mnethodology see . Fig 4 shows that in normal subjects 72-83% of the total daily plasma VLDL Bapoprotein flux was converted to LDL, while 21-28% was degraded without such conversion. The amount of B-apoprotein metabolized by either route was proportionate to the flux rate, and the two pathways accounted for the total VLDL B-apoprotein removed from the plasma.
In cases of endogenous hypertriglyceridxmia (Fig 4) the amount of VLDL B-apoprotein degraded per day was not increased despite a marked increase in the total turnover of this apoprotein. The absolute rate of conversion to LDL, on the other hand, was increased. This increase, however, did not account for the removal of the remaining VLDL B-apoprotein fraction, suggesting that about 17% of the total amount cleared from the plasma was retained in an extravascular compartment. The anatomical location of this compartment and its pathogenic importance in the development of atheroma remains unclear. As shown in Fig 4, we have conducted preliminary experiments to examine the effects of CI-719 on the metabolic fate of plasma VLDL B-apoprotein in 2 hypertriglyceridcmic patients.
It is evident that treatment with the drug restored the absolute conversion of VLDL Bapoprotein into LDL to within the normal range, while the amount degraded per day was not altered. Furthermore, the fraction of plasma VLDL B-apoprotein retained in the extravascular compartment was no longer discernible.
As regards the effects of CI-719 on the metabolic fate of plasma LDL, we have previously reported that in patients treated with this drug the plasma LDL concentration was increased (Kissebah, Alfarsi, Adams, Seed et al. 1976 ). This phenomenon has been observed with clofibrate, a structurally related compound. We have therefore estimated the plasma LDL 125I specific radioactivity, and the daily urinary excretion of 1251 in 2 of our patients over a period of two weeks. The fractional catabolic rate of receiving gemfibrozil (CI-719) therapy plasma LDL was then determined from the urine/plasma ratio, which represents the total 125J excretion per 24 h divided by the total mean plasma isotope level corresponding to the urine collection period. This rate gives an index of the relative efficiency of the LDL catabolic processes. As shown in Table 3 the urine/plasma ratio was reduced during CI-719 therapy, suggesting that the LDL catabolic process has been slowed down, possibly owing to the effects of the drug on hepatic metabolism.
Conclusions
CI-719 is an effective hypotriglyceridcemic drug in patients with endogenous hypertriglycerideemia. It inhibits peripheral lipolysis and decreases the hepatic extraction of plasma FFA, thereby reducing hepatic triglyceride production. The drug also inhibits synthesis of the VLDL carrier apoprotein. The decrease in VLDL production provides the basis for the hypotriglyceridwmic effect of the drug. CI-719 decreases the conversion of VLDL apoprotein to LDL and prevents the retention of VLDL apoprotein in extravascular compartments. On the other hand, the decrease in the catabolic rate of LDL could account for the slight increase in plasma LDL concentration seen during treatment.
